Case study: Biocatalytic production of chiral intermediates

Customer problem

  • Poor enantiomeric excess (e.e.) in preparation of unnatural amino acid (UAA) pharmaceutical intermediates
  • Racemisation during chemical production compromising required pharma grade >99% e.e.

Ingenza solution

  • Enantioselective biocatalytic synthesis of amino acids >99% e.e.
  • Cost effective (chemo)-enzymatic processes and scalable product isolation
  • Technology transfer to CMOs worldwide
  • Versatile and adaptable biocatalysts
  • Inexpensive, low cost raw materials
  • High bioprocess yield
  • Chromatography-free product purification
  • Technology transfer to large scale manufacture at CMO
  • On-site Ingenza staff support
  • Wide range of chiral UAA’s
  • Multi-kg scale from achiral or racemic substrates

Want to Know More?

We’d love to hear from you.